NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hub Group Inc. (NASDAQ:HUBG) for potential violations of the federal securities laws. If you invested in Hub Group, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/hub-group-class-action-lawsuit. Why is Hub Group Being Investigated for Violations of the Federal Securities Laws? Hub Group is a supply chain solutions provider that off ...

Core Viewpoint - Hub Group Inc. is under investigation for potential violations of federal securities laws related to misrepresentation of financial data, specifically concerning purchased transportation costs and accounts payable for the first nine months of 2025 [1][2]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Hub Group for possible misrepresentation of financial information [1]. - The investigation focuses on whether Hub Group inaccurately reported its transportation costs and accounts payable [2]. Group 2: Stock Performance - Hub Group announced a delay in releasing its fourth quarter and full year 2025 financial results, along with a restatement of its financial statements for the first three quarters of 2025 due to an error in reporting purchased transportation costs and accounts payable [3]. - Following this announcement, Hub Group's stock price fell over 24% during trading on February 6, 2026 [4].

Core Insights - PayPal Holdings, Inc. is under investigation for potential securities claims due to a significant discrepancy between its prior outlook and actual fourth quarter 2025 results [1] Group 1: Analyst Expectations and Company Communications - On January 28, 2026, Rothschild & Co Redburn downgraded PayPal's price target from $70 to $50, followed by Morgan Stanley on January 29, 2026, citing slower checkout growth [2] - Analysts had projected mid-single-digit revenue growth and higher earnings per share just one day before the earnings announcement on February 2, 2026 [2] Group 2: Actual Financial Results - PayPal's actual revenue for the fourth quarter 2025 was $8.68 billion, missing the estimate of $8.80 billion by $120 million, representing a 1.4% shortfall [3] - Adjusted earnings per share were reported at $1.23, falling short of the consensus range of $1.30 to $1.33 by 5.4% to 7.5% [3] - The company's forward guidance for 2026 indicated a decline in transaction margin dollars and an adjusted earnings per share range reflecting a low single-digit decline to a slight positive gain, significantly below market expectations [3] Group 3: Management Communication and Market Reaction - During the third quarter 2025 earnings call on October 28, 2025, management did not signal any forthcoming dramatic revisions to the company's outlook [4] - Following the earnings miss on February 3, 2026, PayPal shares dropped 19-20% to approximately $42, marking a new 52-week low, with a reported increase in short interest as traders anticipated further declines [5]

Core Insights - Holzer & Holzer, LLC is investigating whether REGENXBIO Inc. complied with federal securities laws following the announcement of a clinical hold on its Investigational New Drug applications by the FDA [1] - The clinical hold affects two trials: RGX-111 for Mucopolysaccharidosis type I and RGX-121 for Mucopolysaccharidosis type II [1] - Following the announcement, REGENXBIO's stock price experienced a decline [1] Company Information - REGENXBIO Inc. is publicly traded on NASDAQ under the ticker RGNX [1] - The company is focused on developing gene therapies for various diseases, including Mucopolysaccharidosis [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in securities litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Financial Performance - On January 12, 2026, Wealthfront reported its first quarterly results as a public company, revealing net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [4]. - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of Wealthfront's new home-lending business [4]. Group 3: Stock Market Reaction - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from a closing price of $12.59 on January 12, 2026, to $10.47 on January 13, 2026 [4].

Core Viewpoint - Aquestive Therapeutics, Inc. is under investigation for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm, impacting its market commitments and labeling discussions [1]. Company Summary - On January 9, 2026, Aquestive announced it received a letter from the FDA regarding deficiencies in its NDA application for Anaphylm, which is intended for the emergency treatment of anaphylaxis [1]. - Following this announcement, Aquestive's stock price dropped by $2.18, representing a 35.1% decline, opening at $4.03 [2]. Legal Context - Levi & Korsinsky LLP has initiated an investigation into Aquestive Therapeutics, focusing on potential recovery options for investors who may have suffered losses due to the recent developments [2]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [3].

Core Viewpoint - Mereo BioPharma Group plc is under investigation for potential violations of federal securities laws following disappointing clinical trial results that led to a significant drop in stock price [1][2]. Group 1: Company Performance - On December 29, 2025, Mereo BioPharma announced results from its Phase 3 ORBIT and COSMIC studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), reporting that neither study achieved its primary efficacy endpoint of reducing the annualized clinical fracture rate compared to placebo [2]. - Following the announcement, Mereo's stock price plummeted over 89%, opening at $0.25 per share [2]. Group 2: Legal Investigation - Levi & Korsinsky has commenced an investigation into Mereo BioPharma Group plc concerning potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, with strong demand and growth across all channels attributed to distribution expansion and promotional activities [2]. Group 2: Sales Growth Concerns - The sales growth during the relevant period may not be sustainable, as it could have been influenced by temporary inventory loading at key retailers rather than lasting consumer demand [2]. - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply on hand, which would negatively impact growth in Q3 2025 [3]. Group 3: Stock Performance - Following the announcement on May 5, 2025, BellRing's stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company reported disappointing quarterly consumption of Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4].

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][2]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue after conducting evaluations of historical collection trends [3]. - The company increased its professional liability reserves by $54 million due to adverse developments from claims between 2019 and 2022, as well as broader industry trends [3]. Stock Market Reaction - Following the financial report on November 12, 2025, Ardent's stock price dropped over 33% during trading on November 13, 2025 [3].

Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, following disappointing financial results and claims of overstated demand for its Prestige fragrances [1][2][3]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care products [2]. - Prestige fragrances represent 60% of Coty's revenues, indicating a significant reliance on this segment [2]. Group 2: Financial Performance - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as retailer inventory buildup and execution weaknesses in the U.S. market [3]. - The company's stock price fell from $4.86 to $3.81 per share, a decline of over 21%, following the release of these results [3]. Group 3: Market Dynamics - Coty indicated that retailers were maintaining tight inventory levels, while in reality, they were overstocked due to a decline in demand for Coty's products [2]. - The company faced challenges in the cosmetics sector attributed to value-seeking consumer behavior, innovation fatigue, and specific U.S. market factors [3].